Program
difamilast
Also written as “OPA-15406”, “1% OPA-15406 Ointment” and “0.3% OPA-15406 Ointment”.
Its studies are mostly in Dermatitis, Atopic, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Otsuka | 132 open or running | phase 3since Apr 7, 2019 | Oct 3, 2012 | Dec 2026phase 3 · NCT07173478 |
| Aurobindo Pharma | 20 open or running | phase 3since Oct 5, 2022 | Oct 5, 2022 | none ahead |
| Eurofarma Laboratorios | 10 open or running | phase 2since Oct 21, 2016 | Oct 21, 2016 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 3, 2012First study: phase 1 study in Dermatitis, AtopicNew to OtsukaOtsuka · NCT01702181 · 92 enrolled · United States
- Feb 19, 2014Phase 2 study in Dermatitis, AtopicOtsuka · NCT02068352 · 121 enrolled · United States, Australia, Poland
- Jan 5, 2015Phase 1 study in Dermatitis, AtopicOtsuka · NCT02334787 · 32 enrolled · Japan
- Sep 8, 2016Phase 2 study in Dermatitis, AtopicOtsuka · NCT02914548 · 200 enrolled · Japan
- Oct 21, 2016Eurofarma Laboratorios's first study: phase 2 study in Dermatitis, AtopicNew to Eurofarma LaboratoriosEurofarma Laboratorios · NCT02945657 · 32 enrolled · United States, Honduras, Panama
- Jan 6, 2017Phase 2 study in Dermatitis, AtopicOtsuka · NCT03018691 · 73 enrolled · Japan
- Apr 7, 20193 phase 3 studies in Dermatitis, AtopicOtsuka · NCT03908970, NCT03911401, NCT03961529
- May 9, 2022Phase 3 study in Dermatitis, AtopicOtsuka · NCT05372653 · 41 enrolled · Japan
- Oct 5, 2022Aurobindo Pharma's first study: phase 3 study in Dermatitis, AtopicNew to Aurobindo PharmaAurobindo Pharma · NCT05571943 · 542 enrolled · United States
- Nov 1, 2022Phase 3 study in Dermatitis, AtopicAurobindo Pharma · NCT05608343 · 153 enrolled · United States
- Dec 2, 20222 phase 3 studies in Dermatitis, AtopicOtsuka · NCT05667623, NCT05650320
- Sep 7, 20252 phase 3 studies in Dermatitis, AtopicOtsuka · NCT07173478, NCT07184645
Ahead
- Dec 2026Primary completion: phase 3 study in Dermatitis, AtopicOtsuka · NCT07173478
- Feb 2027Primary completion: phase 3 study in Dermatitis, AtopicOtsuka · NCT07184645
TargetBeta
“Phosphodiesterase 4 inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Roflumilastrule | AstraZeneca | phase 4 | 61 |
| apremilastrule | Amgen | phase 4 | 48 |
| ensifentrinerule | Merck | phase 3 | 17 |
| tanimilastrule | Chiesi Farmaceutici | phase 3 | 15 |
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07184645Dermatitis, Atopic · Japan | 3 | Not yet recruiting | Otsuka | Feb 2027 | 198 |
| NCT07173478Dermatitis, Atopic · Japan | 3 | Not yet recruiting | Otsuka | Dec 2026 | 156 |
| NCT05650320Dermatitis, Atopic · China | 3 | Completed | Otsuka | Jul 21, 2024 | 240 |
| NCT05667623Dermatitis, Atopic · China | 3 | Completed | Otsuka | Jun 17, 2024 | 270 |
| NCT05608343Dermatitis, Atopic · United States | 3 | Completed | Aurobindo Pharma | Oct 27, 2023 | 153 |
| NCT05571943Dermatitis, Atopic · United States | 3 | Completed | Aurobindo Pharma | Jul 31, 2024 | 542 |
| NCT05372653Dermatitis, Atopic · Japan | 3 | Completed | Otsuka | Dec 29, 2022 | 41 |
| NCT03961529Dermatitis, Atopic · Japan | 3 | Completed | Otsuka | Nov 11, 2020 | 366 |
| NCT03911401Dermatitis, Atopic · Japan | 3 | Completed | Otsuka | Dec 13, 2019 | 251 |
| NCT03908970Dermatitis, Atopic · Japan | 3 | Completed | Otsuka | Dec 28, 2019 | 364 |
| NCT03018691Dermatitis, Atopic · Japan | 2 | Completed | Otsuka | Jun 2017 | 73 |
| NCT02945657Dermatitis, Atopic · United States, Honduras, Panama | 2 | Completed | Eurofarma Laboratorios | Jun 8, 2017 | 32 |
| NCT02914548Dermatitis, Atopic · Japan | 2 | Completed | Otsuka | Jun 2017 | 200 |
| NCT02334787Dermatitis, Atopic · Japan | 1 | Completed | Otsuka | Feb 2015 | 32 |
| NCT02068352Dermatitis, Atopic · United States, Australia, Poland | 2 | Completed | Otsuka | Jan 28, 2015 | 121 |
| NCT01702181Dermatitis, Atopic · United States | 1 | Completed | Otsuka | Dec 2013 | 92 |
How it is read
Names in the registry
- “OPA-15406”, 7 entries
- “1% OPA-15406 Ointment”, 3 entries
- “0.3% OPA-15406 Ointment”, 2 entries
- “Difamilast”, 2 entries
- “1% OPA-15406”, 2 entries
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 16 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.